Longitudinal evaluation of manufacturer-specific differences for high-sensitive CRP EQA results.

ABSTRACT:

Background

C-reactive protein (CRP) is an established serum biomarker for different pathologies such as tissue injury and inflammatory events. One rising area of interest is the incorporation of low concentrations of CRP, so called high-sensitive (hs-) CRP, in the risk assessment and treatment monitoring of cardiovascular diseases (CVDs). Many research projects and the resulting meta-analyses have reported controversial results for the use of hs-CRP, especially in the risk assessment of CVDs. However, since these analyses used different assays to detect hs-CRP, it is important to assess the current level of assay harmonization.

Methods

This paper analyzes data from 17 external quality assessment (EQA) surveys for hs-CRP conducted worldwide between 2018 and 2023. Each EQA sur

SUBMITTER: Weiss N 

PROVIDER: S-EPMC11338768 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature